• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Chronic - Page 5
Tag:

Chronic

Health

tudy identifies intersectional biases affecting care for sickle cell patients

by Chief Editor April 13, 2026
written by Chief Editor

Sickle Cell Disease and the Fight Against Intersectional Bias in Healthcare

A poignant storyline in the first season of the show “The Pitt” – depicting a Black woman with sickle cell disease initially dismissed as drug-seeking in an emergency department – has sparked renewed attention to systemic biases within healthcare. This isn’t merely a fictional portrayal; experts confirm it reflects a harsh reality for many individuals living with sickle cell disease.

Unpacking the Layers of Bias

Recent research from the University of Chicago Medicine, published in JAMA Network Open, delves into the complex interplay of factors contributing to disparities in care. The study identifies that negative descriptors in clinician notes for sickle cell patients are closely linked to stigma surrounding opioid use, potentially overshadowing the impact of race or chronic pain alone.

View this post on Instagram

Monica Peek, MD, MPH, of UChicago Medicine, explains the challenge of pinpointing the source of discrimination. “Part of the issue for Black patients – and many marginalized groups – is that many in this population have multiple social identities that may be stigmatized… So when patients experience discrimination in healthcare, it is challenging to pinpoint what identity may be triggering the behavior.”

The Data Behind the Disparities

The UChicago Medicine study analyzed electronic health records of over 18,000 adults, examining nearly 40,000 clinician notes for negative descriptors like “aggressive,” “noncooperative,” and “noncompliant.” Findings revealed that patients with sickle cell disease had higher odds of these negative descriptors compared to Black patients and those with chronic pain. However, their odds were similar to patients with opioid use disorder, suggesting a strong connection between bias and opioid stigma.

This builds on previous research showing Black patients are more than 2.5 times more likely to have negative descriptors in their medical records compared to white patients. Further studies have demonstrated that biased language in patient records can lead to decreased clinician empathy and inaccurate recall of critical health details.

Beyond Stigma: The Reality of Pain Management

A key issue highlighted by researchers is the misconception surrounding opioid use in sickle cell disease. While patients often require opioid medications to manage chronic pain, the vast majority do not have an opioid use disorder. “Whereas patients with sickle cell disease routinely use opioid medications to manage their chronic pain, the vast majority do not have an opioid use disorder,” notes Peek. “It is a testament to the strength of their character that they do their best to live full lives while managing debilitating pain.”

Beyond Stigma: The Reality of Pain Management

Austin Wesevich, MD, emphasizes the importance of trust in the patient-clinician relationship. “Clinicians cannot measure pain directly without asking the patient, so it’s a choice to believe patients when they share their pain levels… a patient with sickle cell disease who experiences daily pain and who happens to be Black and asking for opioid treatment deserves no less trust than any other patient.”

Innovative Solutions: Anti-Bias Curriculum

Recognizing the need for change, UChicago Medicine has developed an anti-bias curriculum designed to mitigate these issues. The program utilizes skills-based learning through roleplay, coupled with education on how biases negatively impact care quality. Early data suggests the intervention is effective, with other institutions already expressing interest in adopting the curriculum.

Pro Tip: Healthcare organizations can proactively address bias by implementing similar training programs, promoting diversity within their staff, and fostering a culture of empathy and respect.

Future Trends in Addressing Healthcare Disparities

The focus on intersectional bias in sickle cell care signals a broader trend toward recognizing the complex factors influencing health outcomes. Expect to see increased use of natural language processing (NLP) and machine learning to identify and address bias in electronic health records. The development of standardized pain assessment tools and culturally sensitive communication strategies will be crucial.

The success of the UChicago Medicine intervention highlights the potential of targeted educational programs. Future initiatives may incorporate virtual reality simulations to provide clinicians with immersive experiences that challenge their biases and promote empathy.

FAQ

Q: What is sickle cell disease?
A: A genetic blood disorder that causes red blood cells to become sickle-shaped, leading to pain and other complications.

Q: Why are patients with sickle cell disease often stigmatized?
A: Stigma often stems from misconceptions about pain management and opioid use, as well as racial biases.

Q: What can be done to address bias in healthcare?
A: Implementing anti-bias training, promoting diversity, and fostering a culture of empathy are key steps.

Q: What role does technology play in identifying bias?
A: NLP and machine learning can analyze electronic health records to identify patterns of biased language.

Did you know? Patients with sickle cell disease often experience chronic pain that significantly impacts their quality of life. Effective pain management is essential, but often hindered by bias and stigma.

Learn more about sickle cell disease and ongoing research at the University of Chicago Medical Center.

What are your thoughts on this issue? Share your experiences and insights in the comments below!

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Lab study shows cigarette smoke damaged lung cells more than e-cigarette vapor

by Chief Editor April 13, 2026
written by Chief Editor

Cigarette Smoke vs. E-Cigarettes: Latest Research Reveals Stark Differences in Lung Cell Damage

A groundbreaking laboratory study published in Scientific Reports has revealed significant differences in how cigarette smoke and e-cigarette vapor affect human lung cells. Researchers at the University of Graz, Austria, found that cigarette smoke extract (CSE) caused substantial disruption to lung cell barriers, triggered inflammation, and damaged DNA, while e-cigarette vapor extract (EVE) showed no significant adverse effects under the same experimental conditions.

The Vulnerable Lung Barrier

Our airway epithelium acts as a crucial defense mechanism, protecting the body from inhaled particles and harmful substances. Cigarette smoke is well-established as a damaging agent to this barrier, contributing to conditions like chronic obstructive pulmonary disease (COPD). The question of whether e-cigarettes pose a similar threat has remained a subject of debate.

View this post on Instagram

This study utilized human Calu-3 lung epithelial cells, meticulously cultured and exposed to CSE and EVE. Researchers assessed barrier integrity, inflammation levels, and DNA damage using a range of sophisticated techniques, including Transwell systems, Western blotting, and DNA strand break assays.

CSE’s Damaging Effects: A Cascade of Cellular Disruption

The results were striking. CSE significantly reduced the electrical resistance of the cell barrier, indicating compromised cell cohesion and increased permeability. So harmful substances could more easily penetrate the lung tissue. CSE decreased the expression of key proteins – claudin-1 and occludin – essential for maintaining the integrity of the apical junctional complex, a critical component of the epithelial barrier. A 45% decline in claudin-1 levels was observed, highlighting its vulnerability to smoke exposure.

Inflammation also surged in cells exposed to CSE, with interleukin-6 (IL-6) levels increasing up to tenfold. Significant DNA damage, indicated by increased DNA strand breaks, was also detected. Notably, the study suggests that the damage caused by cigarette smoke isn’t solely attributable to nicotine, implying other toxic components are at play.

EVE: A Different Story

In stark contrast, EVE did not significantly impact barrier integrity, inflammation, or DNA damage. In some instances, it even appeared to slightly improve barrier stability. This suggests that, under the conditions tested in this in vitro model, e-cigarette vapor exerts less harmful effects on lung epithelial cells compared to cigarette smoke.

What Does This Imply for Public Health?

These findings offer valuable insights into the differing impacts of cigarette smoke and e-cigarette vapor on lung health. While CSE demonstrably disrupts cellular defenses, EVE did not exhibit the same detrimental effects. Though, researchers emphasize that this study was conducted in vitro, meaning in a laboratory setting, and doesn’t directly translate to human health outcomes.

The study used unflavored e-liquid, and the authors acknowledge that the use of liquid extracts rather than direct aerosol exposure may limit the generalizability of the findings. Further research, utilizing more representative biological systems, is crucial to fully understand the long-term health effects of e-cigarette vapor.

Pro Tip: Maintaining a healthy lung barrier is vital for overall respiratory health. Avoiding smoke exposure, whether from cigarettes or other sources, is a key step in protecting your lungs.

Future Trends in Respiratory Research

This study underscores a growing trend in respiratory research: the use of advanced in vitro models, like the Calu-3 cell system, to investigate the effects of inhaled substances. Expect to see more research focusing on:

  • Flavoring Chemicals: The impact of various e-liquid flavoring chemicals on lung cells is an area of increasing concern. Studies are beginning to assess the toxicity of cinnamon, vanilla tobacco, and hazelnut flavors.
  • Long-Term Exposure: Most studies to date have focused on short-term exposure. Longitudinal studies are needed to understand the cumulative effects of e-cigarette vapor over years or decades.
  • Individual Variability: Responses to inhaled substances can vary significantly between individuals. Research is exploring how genetic factors and pre-existing conditions influence susceptibility to lung damage.
  • Air-Liquid Interface (ALI) Models: Utilizing ALI models, which more closely mimic the lung environment, will provide more accurate and relevant data.

FAQ

Q: Does this study mean e-cigarettes are safe?
A: No. This study shows that, under the tested conditions, e-cigarette vapor appeared less harmful than cigarette smoke to lung cells. However, it does not prove e-cigarettes are entirely safe, and long-term effects remain unknown.

Q: What is the Calu-3 cell line?
A: Calu-3 is a human lung adenocarcinoma epithelial cell line commonly used in respiratory research to model lung function and responses to inhaled substances.

Q: What is the apical junctional complex?
A: The apical junctional complex is a protein network that forms a seal between lung epithelial cells, maintaining barrier integrity and preventing harmful substances from entering the body.

Q: What is IL-6?
A: IL-6 is an interleukin, a type of signaling molecule involved in inflammation. Elevated IL-6 levels indicate an inflammatory response.

Want to learn more about lung health and respiratory diseases? Explore our extensive library of articles on News-Medical.net.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Rat hepatitis E virus may be a hidden cause of hepatitis in humans

by Chief Editor April 13, 2026
written by Chief Editor

The Hidden Hepatitis Threat: How Rat Hepatitis E Virus is Changing the Disease Landscape

A growing body of evidence points to a surprising source of hepatitis infections in humans: rats. Rat hepatitis E virus (ratHEV), previously considered a rodent-specific virus, is increasingly recognized as a zoonotic threat, prompting a reassessment of global hepatitis burdens and diagnostic approaches. Recent research, published in Nature Communications, details the virus’s ecology, transmission, and clinical impact, raising urgent questions about public health preparedness.

From Rodent Reservoir to Human Infection

For years, hepatitis E virus (HEV) was understood to be primarily transmitted through contaminated water, causing acute hepatitis. However, the discovery of human infection with a Rocahepevirus species in 2018 challenged this understanding. RatHEV, scientifically known as Rocahepevirus ratti, is now confirmed to spill over into humans, with cases reported across Asia, Europe, and even North America. Initial cases were often identified in individuals with unexplained chronic hepatitis, particularly liver transplant recipients.

From Rodent Reservoir to Human Infection

Understanding RatHEV: Genotypes and Viral Structure

Currently, the Rocahepevirus genus includes two species: Rocahepevirus eothenomi and R. Ratti. RatHEV itself has five genotypes (C1 to C5), but genotype C1 appears to be the primary driver of zoonotic transmission. This genotype circulates in both shrews and rats. The virus is a positive-sense, single-stranded RNA virus, with a genome encoding proteins crucial for replication and capsid formation. Genomic analysis reveals significant differences between ratHEV and traditional HEV.

Where is RatHEV Found and How Does it Spread?

RatHEV is widespread in rat populations, particularly in urban environments. Prevalence rates in trapped rats range from 10% to 30%, with higher rates observed in subtropical Asia and southern Europe. Transmission to humans likely occurs through contact with infected rat excreta or potentially through contaminated food or water. Pigs have been identified as potential transient hosts, capable of replicating the virus, and there’s some evidence of exposure in birds of prey, though their role in transmission remains unclear.

The Challenge of Diagnosis and Treatment

Diagnosing ratHEV infection is currently tough. Commercial assays are lacking, and existing antibody tests often show cross-reactivity with traditional HEV antibodies (between 10% and 70% for IgG, and 20% to 40% for IgM). Accurate diagnosis relies on detecting viral RNA through molecular testing, but even this requires multiple qPCR protocols to ensure comprehensive screening.

Clinical presentation mirrors that of HEV, ranging from asymptomatic infection to acute hepatitis, and, in severe cases, fulminant liver failure. In immunocompromised individuals, chronic hepatitis can develop. Treatment currently follows HEV protocols, primarily supportive care or ribavirin. The HEV genotype 1 vaccine may offer partial protection, but clinical efficacy data specifically for ratHEV are still needed.

Public Health Implications and Future Surveillance

The full extent of ratHEV’s impact on human health remains unknown. Systematic surveillance is limited, primarily focused on China and Western Europe. Integrating ratHEV into existing HEV surveillance guidelines could improve diagnosis rates and stimulate further research. International collaboration is crucial for developing standardized diagnostics, harmonizing surveillance efforts, and proactively addressing this emerging zoonotic threat.

FAQ: Rat Hepatitis E Virus

Q: How common is ratHEV infection in humans?
A: Prevalence varies geographically, ranging from less than 1% in some urban areas to as high as 22% in rural China.

Q: Can ratHEV cause chronic hepatitis?
A: Yes, particularly in immunocompromised individuals.

Q: Is the HEV vaccine effective against ratHEV?
A: It may offer partial protection, but more research is needed.

Q: How can I protect myself from ratHEV?
A: Practice good hygiene, avoid contact with rats and their droppings, and ensure proper food safety practices.

Did you know? RatHEV was initially considered strictly host-restricted to rodents, highlighting how our understanding of zoonotic viruses can evolve.

Pro Tip: If you experience unexplained hepatitis and have potential exposure to rats, inform your healthcare provider about the possibility of ratHEV infection.

Stay informed about emerging infectious diseases. Explore our other articles on viral hepatitis and zoonotic diseases to learn more.

April 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

EV-RNAs show promise for IBD diagnosis and treatment

by Chief Editor April 11, 2026
written by Chief Editor

The Future of IBD Treatment: Harnessing the Power of EV-RNAs

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, affects millions worldwide and is projected to impact over 1% of the population in early-industrialized countries by 2045. A recent comprehensive review published in ExRNA, led by researchers at Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, highlights a revolutionary approach to managing this chronic condition: extracellular vesicle-associated RNAs (EV-RNAs).

What are EV-RNAs and Why are They Essential?

EV-RNAs are essentially tiny “biological packages” secreted by cells, containing RNA molecules – including microRNAs and long non-coding RNAs – that act as messengers between cells. These vesicles play a crucial role in regulating the intestinal environment, influencing inflammation, and impacting the gut microbiome. Researchers are discovering that these molecules aren’t just bystanders in IBD, but key regulators that can be targeted for both diagnosis and treatment.

View this post on Instagram

Non-Invasive Diagnosis: A Game Changer

Currently, diagnosing IBD often requires invasive endoscopic examinations. EV-RNAs offer a potential solution with non-invasive biomarkers detectable in easily accessible fluids like plasma and even saliva. Studies cited in the ExRNA review demonstrate remarkably high accuracy – with area under the curve (AUC) values ranging from 0.95 to 0.97 – in distinguishing active IBD from remission using specific EV-RNA signatures, such as elevated levels of long non-coding RNA H19 in plasma EVs.

Pro Tip: The ease of sample collection (saliva, blood) could dramatically improve patient compliance and enable more frequent monitoring of disease activity.

EV-RNA-Based Therapies: Beyond Traditional Approaches

Traditional IBD treatments, like anti-inflammatory drugs and biologics, often come with systemic side effects and can lead to drug resistance. EV-RNA-based therapies offer a more targeted approach. Several strategies are showing promise in preclinical models:

  • Mesenchymal Stem Cell-Derived EVs (MSC-EVs): These EVs carry immunomodulatory miRNAs that can suppress inflammation and promote intestinal barrier repair. They offer a safer alternative to whole-cell stem cell therapy, with a lower risk of immune rejection.
  • Dietary and Plant-Derived EVs: EVs extracted from sources like bovine colostrum, Coptis chinensis, Centella asiatica, and tea contain functional miRNAs that can survive digestion and directly target inflamed intestinal tissues. For example, EVs from Coptis chinensis can restore zinc homeostasis in immune cells, reducing intestinal damage.
  • Engineered EVs: Researchers are modifying EVs to deliver therapeutic RNAs directly to inflamed tissues, offering personalized treatment options for patients who don’t respond to conventional therapies.

Systemic Impact: Addressing Extraintestinal Complications

IBD isn’t limited to the gastrointestinal tract. It’s often associated with complications affecting the liver and heart. The research highlights that EV-RNAs secreted by inflamed intestinal tissues can travel through the bloodstream and influence inflammatory responses in distant organs, providing a molecular link to these systemic issues.

Systemic Impact: Addressing Extraintestinal Complications

Did you know? Understanding the systemic role of gut-derived EV-RNAs could lead to therapies that prevent or mitigate these extraintestinal complications.

Challenges and Future Directions

Despite the exciting potential, several challenges remain. Standardized protocols for EV isolation, purification, and RNA detection are crucial to ensure consistent results across laboratories. Large-scale clinical trials are needed to validate the efficacy of EV-RNA-based diagnostics and therapies in human patients, and clear regulatory pathways for these novel treatments must be established.

Frequently Asked Questions (FAQ)

Q: What is the difference between Crohn’s disease and ulcerative colitis?
A: Crohn’s disease can affect any part of the digestive tract with transmural inflammation, although ulcerative colitis is limited to the colorectal mucosa with superficial inflammation.

Q: Are EV-RNA therapies currently available for IBD patients?
A: No, EV-RNA therapies are still in the preclinical and early clinical stages of development. More research and clinical trials are needed before they become widely available.

Q: How can I learn more about EV-RNA research?
A: You can explore the research published in the journal ExRNA and follow updates from leading research institutions like Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine.

The field of EV-RNA research is rapidly evolving, offering a beacon of hope for the millions affected by IBD. As research progresses and challenges are addressed, these tiny vesicles could revolutionize the way we diagnose, monitor, and treat this debilitating disease.

Want to stay informed about the latest advancements in IBD research? Subscribe to our newsletter for updates and insights from leading experts.

April 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New clinical guidelines address blood clot prevention in pediatric patients

by Chief Editor April 8, 2026
written by Chief Editor

New Guidelines Offer Clarity in Pediatric Blood Clot Prevention

The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have jointly released comprehensive clinical practice guidelines addressing anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE). Published in Blood Advances, these guidelines aim to standardize care for a vulnerable population where preventative strategies have historically lacked consensus.

The Rising Concern of Pediatric VTE

Venous thromboembolism, the formation of blood clots in veins, is becoming increasingly common in children, particularly those hospitalized or managing chronic conditions like cancer. Hospital-acquired VTE is now the second most common cause of preventable harm in children. Previously, much of the data used to guide VTE prevention in pediatric patients was extrapolated from adult studies, which often don’t accurately reflect the unique risk profiles of children.

View this post on Instagram

Key Recommendations for Prophylaxis

The new guidelines, developed by a multidisciplinary expert panel including a lived experience expert, present twelve recommendations and two fine practice statements. These address the complex decision-making process surrounding anticoagulant prophylaxis. Specifically, the guidelines offer conditional recommendations suggesting:

  • No anticoagulant prophylaxis for children with solid cancer, trauma, or critical illness.
  • Anticoagulant prophylaxis for children with antiphospholipid syndrome or those on long-term total parenteral nutrition.

The guidelines as well provide counsel on administering prophylaxis to children with acute lymphoblastic leukemia, lymphoma, a central venous access device, or those who have recently undergone surgery.

Addressing Gaps in Care and Future Research

Recognizing the necessitate for ongoing improvement, the guidelines emphasize the importance of standardized protocols for managing interruptions to therapy, particularly during procedures like lumbar puncture or spinal anesthesia. The expert panel highlighted the need for further research to develop VTE risk assessment models specifically tailored for pediatric populations and to evaluate the safety and efficacy of prophylaxis across different subgroups of children.

“These guidelines provide physicians with an evidence-based framework to make decisions about VTE prophylaxis for children,” said Marisol Betensky, MD, MPH, co-chair of the guidelines.

The Importance of Collaboration

“This patient group is often among the most vulnerable and medically complex we treat, and clinicians have long lacked clear guidance on how to best care for them,” stated ASH President Robert Negrin, MD. The collaboration between ASH and ISTH underscores a shared commitment to advancing evidence-based care and improving outcomes for children worldwide.

The Importance of Collaboration

Resources for Healthcare Professionals

Additional resources, including visual summaries and teaching slides, are available at hematology.org/VTE. ASH and ISTH have also previously developed revised clinical practice guidelines for pediatric VTE treatment.

Frequently Asked Questions

What is VTE? VTE stands for venous thromboembolism, which is the formation of blood clots in veins.

Why are these guidelines significant? They provide a standardized approach to preventing blood clots in children, a population where preventative care has been historically unclear.

Where can I find more information? Visit hematology.org/VTE for additional resources.

Pro Tip: Always consider the individual patient’s risk factors and clinical presentation when making decisions about anticoagulant prophylaxis.

Stay informed about the latest advancements in pediatric hematology. Explore more articles on our website and subscribe to our newsletter for updates.

April 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Higher sugar intake raises gallstone risk in adults, study finds

by Chief Editor March 30, 2026
written by Chief Editor

The Sweet Truth: How Sugar Intake Impacts Gallbladder Health

Recent research is shedding light on a surprising link between our diets and gallbladder health. A new study analyzing data from the National Health and Nutrition Examination Survey (NHANES) reveals a significant association between higher total sugar intake and an increased risk of gallstones in U.S. Adults. This finding underscores the growing concern about the impact of modern dietary habits on chronic disease development.

Gallstones: A Growing Health Concern

Gallstones are a common condition affecting the liver and biliary system. Their prevalence is rising globally, leading to complications like cholecystitis and pancreatitis, which contribute to substantial healthcare costs. Diet plays a crucial role in gallstone formation, and excessive sugar consumption is emerging as a key factor.

NHANES Data Reveals a Clear Connection

Researchers analyzed data from 8,975 participants in the NHANES survey (2017-2023). The study found that for every 100g/day increase in total sugar intake, the risk of gallstones increased by 41%, even after accounting for various lifestyle and dietary factors. Individuals consuming the highest amounts of sugar had an 82% higher risk compared to those with the lowest intake. This association remained consistent across different demographic groups.

The study employed sophisticated machine learning techniques, including XGBoost, to confirm sugar intake as a significant predictor of gallstone risk, ranking it sixth in importance behind age, gender, and BMI. The model demonstrated a high level of accuracy, with an AUC of 0.896.

How Does Sugar Contribute to Gallstone Formation?

The mechanisms linking high sugar intake to gallstone development are complex. Sugar, particularly fructose and sucrose, can alter bile composition and cholesterol metabolism. Increased blood glucose and insulin levels can lead to greater liver cholesterol production and secretion into bile, potentially causing supersaturation. High sugar diets may contribute to insulin resistance, obesity, reduced gallbladder motility, and bile stasis.

Emerging research suggests that excess sugar can also trigger oxidative stress and inflammation, impairing gallbladder function and accelerating cholesterol crystal formation. Disruption of the gut microbiota is another potential pathway, though further investigation is needed.

Sugar-Sweetened Beverages: A Major Culprit

Although the recent study focused on total dietary sugar, other research highlights the specific role of sugar-sweetened beverages (SSBs). A separate analysis of NHANES data (2017-2023) found that every 100 kcal/day increase in SSB consumption was associated with a 10% higher odds of gallstones. Consuming ≥300 kcal/day of SSBs was linked to an 81% higher risk. This relationship was found to be non-linear, suggesting that the risk increases disproportionately with higher SSB intake.

Future Trends and Research Directions

The growing body of evidence linking sugar intake to gallstone risk points to several potential future trends:

  • Increased Public Health Awareness: Expect to see greater emphasis on reducing added sugar consumption in public health campaigns and dietary guidelines.
  • Personalized Nutrition: Advances in genetic testing and microbiome analysis may allow for personalized dietary recommendations to mitigate gallstone risk based on individual susceptibility.
  • Novel Therapeutic Approaches: Research into interventions targeting bile acid metabolism and gut microbiota modulation could lead to new therapies for preventing and treating gallstones.
  • Food Industry Reformulation: Pressure on the food and beverage industry to reduce sugar content in processed foods and drinks is likely to intensify.
  • Longitudinal Studies: Future research will focus on longitudinal studies to establish a causal relationship between sugar intake and gallstone development, and to better understand the underlying mechanisms.

Pro Tip

Read food labels carefully and be mindful of hidden sugars in processed foods. Opt for whole, unprocessed foods whenever possible.

Did You Know?

Gallstones can often be asymptomatic, meaning they don’t cause noticeable symptoms until complications arise. Regular check-ups and a healthy lifestyle are crucial for prevention.

Frequently Asked Questions

  • What are the symptoms of gallstones? Common symptoms include sudden, intense pain in the upper right abdomen, nausea, vomiting, and jaundice.
  • Can gallstones be prevented? Maintaining a healthy weight, eating a balanced diet low in added sugars, and staying physically active can help reduce your risk.
  • Are there any medical treatments for gallstones? Treatment options range from medication to minimally invasive surgery, depending on the severity of the condition.
  • Is fructose worse than other sugars? Research suggests that fructose may have a particularly strong link to metabolic disorders and liver problems, potentially increasing gallstone risk.

Reducing sugar intake is a simple yet powerful step towards improving gallbladder health and overall well-being. By making informed dietary choices, individuals can take control of their health and potentially reduce their risk of developing this common and often painful condition.

Want to learn more about gallbladder health? Explore our articles on liver detoxification and managing chronic inflammation.

March 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Can camel milk improve health? Review highlights benefits but warns against drinking it raw

by Chief Editor March 26, 2026
written by Chief Editor

Camel Milk: From Ancient Remedy to Modern Functional Food – What’s Next?

For centuries, camel milk has been a staple in the diets of communities across arid regions of Africa and Asia, valued not just for sustenance but as well for its perceived medicinal properties. Now, a growing body of scientific research is beginning to validate these traditional beliefs, positioning camel milk as a potential “functional food” with benefits ranging from blood sugar control to improved gut health. Still, a recent review published in Food Science & Nutrition underscores a critical caveat: the safety of consuming raw camel milk.

Unlocking the Nutritional Powerhouse

What sets camel milk apart? Unlike cow’s milk, it contains a distinct protein profile, potentially making it a hypoallergenic alternative for those with dairy sensitivities. Studies suggest it has lower levels of A1 β-casein and β-lactoglobulin, proteins linked to digestive discomfort, and allergies. Camel milk boasts a unique composition of insulin-like proteins, protective exosomes, and antibodies, contributing to its potential therapeutic effects.

Metabolic Health and Type 2 Diabetes

Research indicates promising results in managing Type 2 Diabetes (T2D). A randomized controlled trial found that daily consumption of 500 mL of raw camel milk for three months led to a significant reduction in fasting blood glucose levels in patients with T2D – from 9.89 mmol/L to 6.13 mmol/L. HbA1c levels also saw a notable decrease, dropping from 9.44% to 6.61%.

Neurodevelopmental Benefits and Autism

Beyond metabolic health, studies suggest camel milk may positively impact neurodevelopment. Regular consumption has been linked to improvements in social interaction and language skills in children with autism, potentially due to its antioxidant and anti-inflammatory properties, including reductions in tumor necrosis factor-alpha (TNF-α).

Boosting Immunity and Respiratory Health

Camel milk is rich in lactoferrin, an iron-binding protein with antimicrobial properties. Nutriomics studies have found concentrations ranging from 95 to 250 mg/dL, potentially reducing harmful bacterial loads, including Salmonella species. Research also suggests benefits for respiratory health, with children with asthma experiencing reduced reliance on inhaled corticosteroids and rescue inhalers when incorporating 200 mL of camel milk into their daily diet for two months.

The Raw Milk Risk: A Critical Consideration

Despite the growing evidence of potential benefits, the review strongly cautions against consuming raw camel milk. Testing revealed that 43% of samples tested positive for Salmonella spp., with 31% identified as Salmonella enterica. Outbreaks of brucellosis, linked to Brucella melitensis, have also been associated with raw camel milk consumption. Pasteurization remains essential to mitigate these zoonotic risks.

Future Trends and Research Directions

The future of camel milk as a functional food hinges on several key areas of development:

Standardization and Quality Control

Currently, the camel milk industry lacks standardized production and quality control measures. Establishing clear guidelines for sourcing, processing, and storage will be crucial for ensuring product safety and consistency.

Large-Scale Human Trials

Whereas promising, much of the research relies on smaller studies. Larger, well-designed randomized controlled trials are needed to confirm the observed benefits and determine optimal dosages for various health conditions.

Fermentation and Novel Processing Techniques

Fermented camel milk products, like Dhanaan in Ethiopia, have a long history of traditional apply. Investigating the impact of fermentation on the milk’s nutritional profile and therapeutic properties could unlock new benefits and enhance safety.

Metabolomics and Personalized Nutrition

Utilizing metabolomics – the study of compact molecules – can help bridge the gap between nutritional quality and safety evaluation. This approach could lead to personalized dietary recommendations based on an individual’s metabolic profile and response to camel milk consumption.

FAQ

Q: Is camel milk safe for infants?
A: Research is ongoing. While some studies explore its potential, the review doesn’t definitively state its suitability for infants, and pasteurization is crucial.

Q: What is the difference between camel milk and cow’s milk?
A: Camel milk has a different protein profile, potentially making it more hypoallergenic. It also contains unique bioactive compounds like insulin-like proteins.

Q: Can camel milk cure diabetes?
A: No. However, studies suggest it may help manage blood sugar levels in individuals with Type 2 Diabetes.

Q: Is raw camel milk safe to drink?
A: No. The review highlights significant risks of zoonotic diseases associated with raw camel milk consumption.

Did you grasp? Camel milk can remain fresh for up to 12 days when stored at 2°C, significantly longer than cow’s milk.

Explore more articles on functional foods and nutritional science to stay informed about the latest advancements in health and wellness.

March 26, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Systematic review identifies stress-induced biological triggers in oncology

by Chief Editor March 25, 2026
written by Chief Editor

The Silent Threat: How Chronic Stress is Rewriting the Rules of Cancer Care

Stress is an unwelcome, yet constant, companion for anyone facing a cancer diagnosis. But emerging research reveals it’s far more than just an emotional burden. Chronic stress is increasingly recognized as a biological factor that can influence cancer progression, treatment response, and survival rates. A recent systematic review from Wroclaw Medical University, published in the International Journal of Molecular Sciences, underscores this critical connection, prompting a re-evaluation of how we approach cancer care.

The Three-Stage Cascade: How Stress Impacts Cancer

Researchers are uncovering the intricate mechanisms linking chronic stress to the course of cancer. These mechanisms can be broadly categorized into three interconnected stages. First, a sustained “hormonal alarm” is triggered, leading to persistently elevated levels of cortisol, adrenaline, and noradrenaline. This constant state of alert, as co-author Katarzyna Herbetko explains, results in increased inflammation and immunosuppression – conditions that can fuel tumor growth and hinder treatment effectiveness.

Second, these stress hormones directly impact the immune system, weakening its ability to identify and eliminate cancer cells. Prolonged exposure shifts the balance towards chronic, low-grade inflammation, creating a fertile environment for cancer to thrive. Finally, at the tissue level, chronic stress can disrupt crucial processes like angiogenesis (blood vessel formation) and contribute to treatment resistance.

Not One-Size-Fits-All: Cancer Type Matters

The impact of chronic stress isn’t uniform across all cancers. The review highlights significant differences based on prognosis. In cancers with generally better survival rates, like breast and prostate cancer, stress often manifests as chronic uncertainty – the long-term fear of recurrence and the challenges of adapting to life after treatment. Here, hormonal signaling pathways play a key role, potentially influencing metastasis and treatment response.

However, in cancers with poorer prognoses, such as pancreatic and ovarian cancer, psychological distress and depression are more prevalent and severe. Interestingly, these psychological symptoms can sometimes precede a cancer diagnosis, suggesting a biological link rather than simply a reaction to the illness. Inflammatory and cytokine mechanisms, including elevated IL-6 levels, appear to be dominant in these cases.

Pro Tip: Recognizing the unique stress profile associated with different cancer types is crucial for tailoring interventions and improving patient outcomes.

Beyond Talk Therapy: The Biological Impact of Psychotherapy

The review emphasizes that psychotherapy in oncology is not merely emotional support; it’s a potentially powerful biological intervention. Studies demonstrate that psychological interventions can reduce anxiety and depression, improve quality of life, and even influence stress and inflammation markers like cortisol levels and cytokine production.

However, researchers caution against oversimplification. While measurable biological changes are observed, a direct correlation between psychotherapy and increased survival rates remains elusive. The benefits of psychological therapy may diminish after its completion, highlighting the need for sustained, long-term support.

Future Trends: Integrating Psycho-Oncology into Standard Care

The growing body of evidence points towards a fundamental shift in cancer care: the integration of psycho-oncology as a standard component of treatment. This includes routine screening for distress, rapid access to assistance, and support for both patients and their caregivers.

Several emerging trends are poised to further enhance this integration:

  • Digital Interventions (e-Health): Mobile apps and online platforms offering stress management techniques, mindfulness exercises, and peer support networks are becoming increasingly accessible.
  • Personalized Stress Management: Advances in biomarkers and genetic testing may allow for the identification of individuals most vulnerable to the negative effects of stress, enabling tailored interventions.
  • Focus on the Tumor Microenvironment: Research is expanding to explore how stress-induced changes in the tumor microenvironment impact treatment response and resistance.
  • Caregiver Support Programs: Recognizing the significant stress experienced by caregivers is crucial, and dedicated support programs are gaining traction.

FAQ: Chronic Stress and Cancer

Q: Is stress a direct cause of cancer?
A: While stress doesn’t directly cause cancer, it can create a biological environment that promotes cancer progression and hinders treatment effectiveness.

Q: What are some practical ways to manage stress during cancer treatment?
A: Techniques like mindfulness, meditation, yoga, deep breathing exercises, and connecting with support groups can be helpful.

Q: Is there a specific type of therapy that’s most effective for cancer-related stress?
A: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) have shown promise in managing stress and improving coping mechanisms.

Q: How can family and friends best support a loved one undergoing cancer treatment?
A: Offer practical help, listen without judgment, and encourage them to seek professional support when needed.

The message is clear: chronic stress is not a patient’s failing, but a modifiable risk factor that deserves clinical attention. By recognizing the biological impact of stress and integrating psycho-oncology into standard care, we can move towards a more holistic and effective approach to cancer treatment.

Want to learn more about managing stress and improving your well-being during cancer treatment? Explore additional resources on the National Cancer Institute website.

March 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Breast reduction surgery is linked to lower diabetes and heart risk

by Chief Editor March 24, 2026
written by Chief Editor

Beyond Aesthetics: Could Breast Reduction Be a Metabolic Game Changer?

For decades, breast reduction surgery has been recognized for its ability to alleviate physical discomfort and improve quality of life. But emerging research suggests this procedure may offer benefits that extend far beyond the cosmetic – potentially impacting long-term metabolic health. A recent study analyzing data from over 23,000 women indicates a link between breast reduction and a reduced risk of conditions like type 2 diabetes and hypertension.

The Unexpected Connection: Macromastia and Metabolic Risk

Traditionally, breast reduction surgery has addressed issues like chronic back, neck, and shoulder pain, skin irritation, and limitations in physical activity. Patients often report significant improvements in self-esteem and body image following the procedure. Though, the potential for systemic metabolic effects is a relatively new area of investigation. Previous research on fat removal procedures, such as liposuction, has hinted at metabolic improvements, but the impact of breast tissue reduction remained less clear.

Study Highlights: Lower Risks Across the Board

The study, currently available on the SSRN preprint server, categorized patients by body mass index (BMI) to assess the impact of surgery. Researchers found that women who underwent breast reduction experienced notable reductions in several metabolic risk factors. Specifically, in the BMI 25-30 group, surgery was associated with lower rates of diabetes, low HDL cholesterol, elevated blood pressure, and metabolic syndrome. Similar benefits were observed in the BMI 30-35 group, though the reduction in diabetes risk wasn’t statistically significant in this cohort.

Interestingly, the benefits appeared most pronounced in normal-weight and overweight patients. This suggests that the metabolic impact of breast reduction may be influenced by a patient’s baseline weight and overall health status.

How Might This Perform? Unpacking the Potential Mechanisms

Even as the study establishes an association, it doesn’t definitively prove causation. Several theories attempt to explain the observed metabolic benefits. Reducing the weight of breast tissue could alleviate chronic inflammation, a known contributor to insulin resistance and cardiovascular disease. Improved physical activity levels post-surgery may play a role in enhancing metabolic function. The removal of hormonally active breast tissue is another potential factor, though further research is needed to explore this connection.

Diabetes and Heart Health: A Closer Look at the Data

The study revealed that after accounting for various factors, women who had breast reduction surgery had a lower prevalence of type 2 diabetes, hypertension, and disorders of lipoprotein metabolism compared to those who did not. For example, in the BMI 30-35 group, the prevalence of hypertension was 12.36% in the surgery group versus 4.94% in the control group before propensity score matching. These findings align with recent research linking breast reduction surgery to lower diabetes and heart risk.

Important Considerations and Future Research

Researchers acknowledge that residual confounding and differences in healthcare access could contribute to the observed associations. The study also excluded patients with a history of breast cancer or those who had undergone other body contouring procedures, limiting the generalizability of the findings. Further research, including randomized controlled trials, is needed to confirm these results and elucidate the underlying mechanisms.

Did you understand? The American Society of Plastic Surgeons guidelines already emphasize the need for more evidence regarding glycemic control in patients with diabetes undergoing breast reduction surgery.

FAQ

Q: Does breast reduction surgery guarantee I won’t develop diabetes or heart disease?
A: No, it doesn’t guarantee prevention, but the study suggests it may lower your risk.

Q: Is this benefit seen in all patients?
A: The benefits appear more pronounced in normal-weight and overweight individuals.

Q: What further research is needed?
A: Randomized controlled trials are needed to confirm these findings and understand the mechanisms involved.

Pro Tip: Discuss your individual risk factors and potential benefits with a qualified healthcare professional before considering breast reduction surgery.

Want to learn more about the impact of surgery on overall health? Explore our articles on metabolic syndrome and the link between inflammation and chronic disease.

Have questions about breast reduction surgery or its potential health benefits? Share your thoughts in the comments below!

March 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Study highlights neurological and psychiatric impacts of long COVID

by Chief Editor March 23, 2026
written by Chief Editor

The Long Shadow of COVID: Navigating a Chronic Illness and its Future

Nearly three years after the acute phase of the SARS-CoV-2 pandemic subsided, a significant global health challenge remains: Long COVID. Conservative estimates suggest between 80 million and 400 million people worldwide are living with this chronic condition, impacting their quality of life and straining healthcare systems. The condition is characterized by over 200 symptoms, ranging from debilitating fatigue and shortness of breath to complex neuropsychiatric issues like cognitive dysfunction and memory loss.

Unraveling the Biological Mysteries of Long COVID

Researchers are actively investigating the underlying mechanisms driving Long COVID. Several factors appear to be at play, including the persistence of the SARS-CoV-2 virus within the body, reactivation of herpesviruses due to immune system stress, and chronic immune activation. Further complexities arise from immune system dysregulation, imbalances in gut microbiota, coagulation abnormalities, and damage to the endothelial lining of blood vessels. Neurological impacts, including structural brain changes and altered functional connectivity, are also being observed.

The Neurological and Psychological Toll

A recent review published in Nature Reviews Disease Primers provides a comprehensive overview of the neurological, psychological, and psychiatric manifestations associated with Long COVID. This analysis highlights the profound impact on cognitive function, mental health, and overall well-being. Professor Clarissa Yasuda, a neurologist from the State University of Campinas in Brazil, contributed to this review, emphasizing the need for continued research and effective treatments.

The Economic Burden: Lost Work Hours and Global Impact

The economic consequences of Long COVID are substantial. A 2024 study estimated that Long COVID resulted in over 803 million lost work hours in Brazil alone, translating to a potential economic loss exceeding USD 11 billion. Globally, the estimated annual economic impact could reach approximately USD 1 trillion – roughly 1% of the global economy. This highlights the urgent need for effective prevention and management strategies.

Diagnosis and the Challenge of Biomarkers

Currently, diagnosis of Long COVID relies heavily on clinical evaluation. There are no approved biomarkers to definitively identify the condition. A recent history of SARS-CoV-2 infection, coupled with persistent or recurrent symptoms lasting at least three months, are key diagnostic criteria. Ruling out other potential conditions often requires blood tests, imaging, and cardiovascular assessments.

Brazil’s Experience with Long COVID

While reported COVID-19 cases in Brazil have decreased in recent years – approximately 432,400 cases in 2025 compared to 984,000 the previous year – the prevalence of Long COVID remains significant. Brazil’s national public health system, the SUS, has been monitoring the condition since 2021. Epidemiological data from 2025 estimates 13.8 million cases of “post-COVID conditions” in the country, with women and individuals aged 30-49 being disproportionately affected.

Addressing Stigma and Promoting Multidisciplinary Care

Patients with Long COVID often face stigma, discrimination, and inadequate access to care. These experiences can create barriers to diagnosis, treatment, and social support. Researchers emphasize the importance of multidisciplinary care teams, involving professionals from various health fields, to address the complex needs of individuals with Long COVID. Particular attention should be paid to the experiences of ethnic minorities and the impact on children and adolescents.

Future Research Directions

Future research efforts should prioritize recruiting diverse and representative patient populations and incorporating the perspectives of individuals living with Long COVID. Understanding the role of social and health determinants is also crucial. Professor Yasuda’s group is currently conducting a longitudinal study to investigate how Long COVID alters brain function, contributing to the growing body of knowledge on this complex condition.

FAQ: Long COVID

Q: What is the best way to prevent Long COVID?
A: Avoiding SARS-CoV-2 infection is currently the most effective way to prevent Long COVID.

Q: Is Long COVID the same for everyone?
A: No, Long COVID presents differently in each individual, with over 200 reported symptoms.

Q: Are there any specific tests to diagnose Long COVID?
A: Currently, there are no approved biomarkers for Long COVID. Diagnosis relies on clinical evaluation and ruling out other conditions.

Q: What kind of support is available for people with Long COVID?
A: Multidisciplinary care teams are recommended, and national health systems like Brazil’s SUS are monitoring and providing support for post-COVID conditions.

Did you know? Even individuals who experience mild or no symptoms during an initial COVID-19 infection can develop Long COVID.

Pro Tip: Vaccination and avoiding reinfection are key strategies to minimize the risk of developing Long COVID.

Have you or someone you know been affected by Long COVID? Share your experiences and insights in the comments below. Explore our other articles on chronic illness and preventative health for more information.

March 23, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Jill Peeters Reveals Next Week’s Temperature Forecast

    June 20, 2026
  • How to Build Muscle Effectively: A Proven Guide

    June 20, 2026
  • Helena Bergström Exposes Scandalous Affair with Married Director Colin Nutley

    June 20, 2026
  • Official: Wieczysta Krakow Secures Major Signing, Beating Legia and Rakow

    June 20, 2026
  • St. Theodore Stratilates Day: Orthodox Traditions in Latvia (June 21, 2026)

    June 20, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World